[1] GUO C, WANG J, CAO F, et al. Lyotropic liquid crystal systems in drug delivery[J]. Drug Discov Today, 2010, 15(23):1032-1040.
[2] AZMI I D, MOGHIMI S M, YAGHMUR A. Cubosomes and hexosomes as versatile platforms for drug delivery [J]. Ther Deliv, 2015, 6(12):1347-1364.
[3] CHONG J Y T, MULET X, WADDINGTON L J, et al. High-throughput discovery of novel steric stabilizers for cubic lyotropic liquid crystal nanoparticle dispersions[J]. Langmuir, 2012, 28(25):9223-9232.
[4] ZHAI J, WADDINGTON L, WOOSTER T J, et al. Revisiting β-casein as a stabilizer for lipid liquid crystalline nanostructured particles[J]. Langmuir, 2011, 27(24):14757-14766.
[5] ELNAGGAR Y S, ETMAN S M, ABDELMONSIF D A, et al. Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer′s disease: pharmaceutical, biological, and toxicological studies[J]. Int J Nanomed, 2015, 10(1):5459-5473.
[6] ELGINDY N A, MEHANNA M M, MOHYELDIN S M. Self-assembled nano-architecture liquid crystalline particles as a promising carrier for progesterone transdermal delivery [J]. Int J Pharm, 2016, 501(1-2): 167-179.
[7] AZHARI H, STRAUSS M, HOOK S, et al. Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the blood-brain barrier[J]. Eur J Pharm Biopharm, 2016, 104:148-155.
[8] RAJABALAYA R, MUSA M N, KIFLI N, et al. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals[J]. Drug Des Develop Ther, 2017, 11:393-406.
[9] CHEN Y, MA P, GUI S. Cubic and hexagonal liquid crystals as drug delivery systems[J]. Biomed Res Int, 2014, 2014(1):1-12.
[10] JAIN S, BHANKUR N, SWARNAKAR N K, et al. Phytantriol based “Stealth” lyotropic liquid crystalline nanoparticles for improved antitumor efficacy and reduced toxicity of docetaxel[J]. Pharm Res, 2015,32(10):3282-3292.
[11] LUO Q, LIN T, ZHANG C Y, et al. A novel glyceryl monoolein-bearing cubosomes for gambogenic acid: preparation, cytotoxicity and intracellular uptake[J]. Int J Pharm, 2015, 493(1-2):30-39.
[12] PENG X, ZHOU Y, HAN K, et al. Characterization of cubosomes as a targeted and sustained transdermal delivery system for capsaicin[J]. Drug Des Develop Ther, 2015, 9:4209-4218.
[13] ACHOURI D, HORNEBECQ V, PICCERELLE P, et al. Self-assembled liquid crystalline nanoparticles as an ophthalmic drug delivery system. Part I: influence of process parameters on their preparation studied by experimental design[J]. Drug Dev Ind Pharm, 2015, 41(1):109-115.
[14] AMAR-YULI I, WACHTEL E, SHOSHAN E B, et al. Hexosome and hexagonal phases mediated by hydration and polymeric stabilizer[J]. Langmuir, 2007, 23(7):3637-3645.
[15] DONG A W, FONG C, WADDINGTON L J, et al. Application of positron annihilation lifetime spectroscopy (PALS)to study the nanostructure in amphiphile self-assembly materials: phytantriol cubosomes and hexosomes[J]. Phys Chem Chem Phys, 2014, 17(3):1705-1715.
[16] KUNTSCHE J, HORST J C, BUNJES H. Cryogenic transmission electron microscopy (cryo-TEM)for studying the morphology of colloidal drug delivery systems[J]. Int J Pharm, 2011,417(1):120-137.
[17] WANG Z N, ZHENG L Q. Progress in cubic phase of lipid liquid crystal as drug delivery system [J]. Prog Chem, 2005, 17(3):417-422.
[18] MELI V, CALTAGIRONE C, FALCHI A M, et al. Docetaxel-loaded fluorescent liquid-crystalline nanoparticles for cancer theranostics[J]. Langmuir, 2015, 31(35):9566-9575.
[19] DONG Y D, BOYD B J. Applications of X-ray scattering in pharmaceutical science[J]. Int J Pharm, 2011, 417(1-2):101-111.
[20] AVACHAT A M, PARPANI S S. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz[J]. Colloids Surf B Biointerfaces, 2015, 126:87-97.
[21] BOYD B J, RIZWAN S B, DONG Y D, et al. Self-assembled geometric liquid-crystalline nanoparticles imaged in three dimensions: hexosomes are not necessarily flat hexagonal prisms[J]. Langmuir, 2007, 23(23):12461-12464.
[22] JIN X, ZHANG Z H, LI S L, et al. A nanostructured liquid crystalline formulation of 20(S)-protopanaxadiol with improved oral absorption[J]. Fitoterapia, 2013, 84(1):64-71.
[23] NGUYEN T H, HANLEY T, PORTER C J, et al. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration[J]. J Controlled Release, 2011, 153(2):180-186.
[24] YANG Z, TAN Y, CHEN M, et al. Development of amphotericin B-loaded cubosomes through the Solemuls technology for enhancing the oral bioavailability[J]. AAPS Pharm Sci Tech, 2012, 13(4):1483-1491.
[25] BOYD B J, KHOO S M, WHITTAKER D V, et al. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats[J]. Int J Pharm, 2007, 340(1-2):52-60.
[26] LAJ J, LU Y, YIN Z, et al. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles[J]. Int J Nanomed, 2010, 5(1):13-23.
[27] YANG Z, CHEN M, YANG M, et al. Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection[J]. Int J Nanomed, 2014, 9(1):327-336.
[28] CERVIN C, VANDOOLAEGHE P, NISTOR C, et al. A combined in vitro and in vivo study on the interactions between somatostatin and lipid-based liquid crystalline drug carriers and bilayers[J]. Eur J Pharm Sci, 2009, 36(4-5): 377-385.
[29] NASR M, GHORAB M K, ABDELAZEM A. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting[J]. Acta Pharm Sin B(药学学报英文), 2015, 5(1):79-88.
[30] THAPA R K, YOO B K. Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation[J]. J Dermatol Treat, 2014, 25(1):22-25.
[31] LOPES L B, SPERETTA F F, BENTLEY M V. Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems[J]. Eur J Pharm Sci, 2007, 32(3):209-215.
[32] GAN L, HAN S, SHEN J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability[J]. Int J Pharm, 2010, 396(1-2):179-187.
[33] SWARNAKAR N K, JAIN V, DUBEYV, et al. Enhanced oromucosal delivery of progesterone via hexosomes[J]. Pharm Res, 2007, 24(12):2223-2230.
[34] CLOGSTON J, CRACIUN G, HART D J, et al. Controlling release from the lipidic cubic phase by selective alkylation [J]. J Controlled Release, 2005,102(2):441-461.
[35] BARAUSKAS J, JOHNSSON M, TIBERG F. Self-assembled lipid superstructures: beyond vesicles and liposomes [J]. Nano Lett, 2005,5(8):1615-1619.
[36] BARAUSKAS J, CERVIN C, JANKUNEC M, et al. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes [J]. Int J Pharm, 2010, 391(1):284-291.
[37] TRAN N, MULET X, HAWLEY A M, et al. Nanostructure and cytotoxicity of self-assembled monoolein-capric acid lyotropic liquid crystalline nanoparticles[J]. Rsc Adv, 2015, 5(34):26785-26795.